4.8 Editorial Material

Aspirin-another caloric-restriction mimetic

Journal

AUTOPHAGY
Volume 14, Issue 7, Pages 1162-1163

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/15548627.2018.1454810

Keywords

Acetylation; aging; AMPK; autophagy; C. elegans; inflammation; fasting; longevity; mitophagy; salicylate

Categories

Funding

  1. Ligue contre le Cancer
  2. Agence National de la Recherche (ANR) - Projets blancs
  3. ANR under the frame of E-Rare-2
  4. ERA-Net for Research on Rare Diseases
  5. Association pour la recherche sur le cancer (ARC)
  6. Canceropole Ile-de-France
  7. Chancelerie des universites de Paris (Legs Poix)
  8. Fondation pour la Recherche Medicale (FRM)
  9. European Commission (ArtForce)
  10. European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR)
  11. European Research Council (ERC)
  12. Fondation Carrefour
  13. Institut National du Cancer (INCa)
  14. Inserm (HTE)
  15. Institut Universitaire de France
  16. LeDucq Foundation
  17. LabEx Immuno-Oncology
  18. RHU Torino Lumiere
  19. Seerave Foundation
  20. SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
  21. SIRIC Cancer Research and Personalized Medicine (CARPEM)
  22. Paris Alliance of Cancer Research Institutes (PACRI)

Ask authors/readers for more resources

The capacity of cells and organisms to sustain, and to eventually adapt to, environmental and genetic insults declines with age. Because macroautophagy/autophagy is regarded as one of the major determinants of cellular fitness in vitro and in vivo, maneuvers that aim at promoting autophagy may slow down aging and promote health span. Caloric restriction (CR), a reduction in caloric intake without malnutrition, efficiently counteracts aging-associated features, yet is difficult to be applied to humans. Caloric-restriction mimetics (CRMs) are pharmacological agents that recapitulate the main biochemical properties of CR, namely a global reduction of protein acetylation and the induction of autophagy. We found that the ancient drug aspirin and its active metabolite salicylate stimulate autophagic flux by virtue of their inhibitory action on acetyltransferase EP300. The inhibition of EP300 results from a direct competition between salicylate and acetyl coenzyme A for binding to the catalytic domain of the enzyme. This mode of action appears to be conserved across evolution as it accounts for the induction of autophagy by aspirin in various mouse models and in the nematode Caenorhabditis elegans. In sum, aspirin acts as a CRM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available